|
Market Closed -
Nasdaq
16:00:00 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 27.28 USD | +1.56% |
|
+11.80% | -22.46% |
| 10-28 | Viking Therapeutics, Inc., Q3 2026 Earnings Call, Oct 28, 2026 | |
| 10-28 | Earnings Flash (VKTX) Viking Therapeutics Posts Q3 Loss -$1.55, vs. FactSet Est of -$1.06 Loss | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.48B | - | - | - | - | - |
| 63.77B | |||||
| 56.37B | |||||
| 54.62B | |||||
| 44.06B | |||||
| 42.11B |
Select your edition
All financial news and data tailored to specific country editions
